Washington, DC: The director of the US National Institute on Drug Abuse (NIDA), Nora Volkow, believes that cannabidiol (CBD) - a nonpsychotropic cannabinoid - is "a safe drug with no addictive effects." Volkow made the comments in an op-ed published last week by The Huffington Post.
Volkow further acknowledged, "[P]reliminary data suggest that it may have therapeutic value for a number of medical conditions."
Preclinical studies have documented CBD to possess a variety of therapeutic activities, including anti-cancer properties, anti-diabetic properties, and bone-stimulating activity. Clinical and observational trials have documented the substance to possess anxiolytic, anti-psychotic, and anti-seizure activity in humans. Safety trials have further concluded the substance to be "safe and well tolerated" when administered to healthy subjects.
To date, 15 states have enacted laws specifically permitting the possession of high-CBD formulated extracts for therapeutic purposes, primarily for the treatment of pediatric epilepsy.
In a recent Time Magazine op-ed, Democrat Sen. Diane Feinstein (CA) and Republican Sen. Charles Grassley (IA) encouraged the Obama administration to "definitively determine if CBD has scientific and medical benefits," and to "look at expanding compassionate access programs where possible, to benefit as many children as possible."
Under federal law, CBD - like cannabis - is defined as a Schedule I controlled substance with "a high potential for abuse ... no currently accepted medical use, ... [and] a lack of accepted safety for the use of the drug ... under medical supervision."
For more information, please contact Allen St. Pierre, NORML Executive Director, at (202) 483-5500 or Paul Armentano, NORML Deputy Director, at email@example.com.